Cargando…

Advances in genetics. Volume 84 /

The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Friedmann, Theodore, 1935-, Dunlap, Jay C., Goodwin, Stephen F.
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Waltham, MA : Elsevier Science, 2013.
Edición:First edition.
Temas:
Acceso en línea:Texto completo
Texto completo

MARC

LEADER 00000cam a2200000 i 4500
001 SCIDIR_ocn900564360
003 OCoLC
005 20231117044931.0
006 m o d
007 cr |n|||||||||
008 131130s2013 mau o 000 0 eng d
040 |a YDXCP  |b eng  |e pn  |c YDXCP  |d OCLCO  |d OCLCQ  |d OCLCF  |d EBLCP  |d OPELS  |d N$T  |d DEBSZ  |d OCLCQ  |d D6H  |d OTZ  |d UKBTH  |d OCLCQ  |d VT2  |d OCLCO  |d OCLCQ  |d OCLCO 
019 |a 864414797 
020 |a 9780124077317  |q (electronic bk.) 
020 |a 0124077315  |q (electronic bk.) 
020 |z 9780124077034 
035 |a (OCoLC)900564360  |z (OCoLC)864414797 
050 4 |a QH430  |b .A38 2013 
072 7 |a SCI  |x 027000  |2 bisacsh 
082 0 4 |a 576.5  |2 23 
245 0 0 |a Advances in genetics.  |n Volume 84 /  |c edited by, Theodore Friedmann, Jay C. Dunlap, Stephen F. Goodwin. 
250 |a First edition. 
260 |a Waltham, MA :  |b Elsevier Science,  |c 2013. 
300 |a 1 online resource (163 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The field of genetics is rapidly evolving, and new medical breakthroughs are occurring as a result of advances in our knowledge of genetics. This series continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines. 
588 0 |a Online resource; title from digital title page (viewed on Apr 3, 2014). 
505 0 |a Front Cover; Advances in Genetics; Copyright; Contents; Contributors; Chapter One: Diverse Roles for MAPK Signaling in Circadian Clocks; 1. Circadian Clocks; 1.1. The beginning; 1.2. Organization of the circadian clock; 2. MAPK Signaling Pathways; 2.1. General organization; 2.2. ERK MAPK; 2.3. p38 MAPK; 2.4. JNK MAPK; 3. The Function of MAPKs in Circadian Input Pathways; 3.1. ERK MAPK pathway; 3.2. ERK signaling through downstream components; 3.3. ERK MAPK in peripheral tissues; 3.4. p38 MAPK pathway; 3.5. p38 MAPK in peripheral tissues; 3.6. JNK MAPK pathway; 3.7. Summary 
505 8 |a 4. Endogenous Rhythms in MAPK Activation4.1. ERK in the SCN; 4.2. p38 and JNK MAPK; 4.3. Transcriptional regulation of MAPK components; 4.4. Transcriptional regulation of MAPK components in mammalian peripheral tissue; 4.5. Rhythmic MAPK activity gates input to the circadian clock; 5. MAPKs Modulate the Circadian Oscillator; 5.1. ERK-mediated regulation of the circadian oscillator; 5.2. p38-mediated regulation of the circadian oscillator; 5.3. JNK-mediated regulation of the circadian oscillator; 5.4. Future directions; 6. The Role of MAPK Pathways in Circadian Output; 6.1. ERK MAPK pathway 
505 8 |a 6.2. p38 MAPK pathway6.3. JNK MAPK pathway; 6.4. Future directions; 7. Concluding Remarks; References; Chapter Two: Stakeholder Views on Returning Research Results; 1. Introduction; 2. What is a Research Result?; 3. Guidelines on Returning Research Results; 3.1. Biobanks; 3.2. Population-based studies; 4. Stakeholder Views; 4.1. Researchers; 4.2. IRBs; 4.3. Research participants; 4.3.1. Vulnerable populations: Children; 4.3.2. Underserved minority populations; 4.3.3. Returning research results to relatives of research participants; 5. Extent and Experience with Returning Research Results 
505 8 |a 6. Overall Analysis of Stakeholder Positions6.1. Ethical; 6.2. Legal; 7. Additional Points to Consider; 7.1. Informed consent for returning research results; 7.2. Communication of research results; 7.3. Impact of returning results to affected versus healthy participants; 7.4. Provision of follow-up care; 7.5. Cost; 8. Moving Forward; Acknowledgment; References; Chapter 3: Mouse Models of Radiation-Induced Cancers; 1. Introduction; 2. RI Leukemia; 2.1. RF model; 2.2. SJL/J model; 2.3. C3H model; 2.4. CBA model; 2.5. Underlying molecular pathologies of RI leukemia; 3. RI Lymphoma 
505 8 |a 3.1. C57BL model3.2. BALB/c model; 3.3. NFS model; 3.4. Underlying molecular pathologies of RI lymphoma; 4. RI Lung Cancer; 4.1. C3H model; 4.2. RF model; 4.3. BALB/c model; 4.4. Underlying molecular pathologies of RI lung cancer; 5. RI Breast Cancer; 5.1. BALB/c total body irradiation model; 5.2. BALB/c transplantation model; 5.3. Underlying molecular pathologies of RI breast cancer; 6. Discussion and Conclusions; References; Chapter Four: Genomics of Elite Sporting Performance: What little We Know and Necessary Advances; 1. Introduction 
650 0 |a Genetics. 
650 6 |a G�en�etique.  |0 (CaQQLa)201-0069234 
650 7 |a genetics.  |2 aat  |0 (CStmoGRI)aat300138822 
650 7 |a SCIENCE  |x Life Sciences  |x Evolution.  |2 bisacsh 
650 7 |a Genetics  |2 fast  |0 (OCoLC)fst00940117 
700 1 |a Friedmann, Theodore,  |d 1935- 
700 1 |a Dunlap, Jay C. 
700 1 |a Goodwin, Stephen F. 
776 0 8 |i Print version:  |a Friedmann, Theodore.  |t Advances in Genetics.  |d Burlington : Elsevier Science, �2013  |z 9780124077034 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/book/9780124077034  |z Texto completo 
856 4 0 |u https://sciencedirect.uam.elogim.com/science/bookseries/00652660/84  |z Texto completo